Kaleido Biosciences, Inc. (KLDO) |
|
0.0003 0 (50%)
|
01-27 10:29 |
|
Open: |
0.0004 |
Pre. Close: |
0.0002 |
|
High:
|
0.0004 |
Low:
|
0.0003 |
|
Volume:
|
757 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:51 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0 One year: 0.01 |
| Support: |
Support1: 0 Support2: 0 |
| Resistance: |
Resistance1: 0 Resistance2: 0 |
| Pivot: |
0  |
| Moving Average: |
MA(5): 0 MA(20): 0
MA(100): 0 MA(250): 0.3 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 0.5 %D(3): 12.2 |
| RSI: |
RSI(14): 34.8  |
| 52-week: |
High: 1.91 Low: 0 |
| Average Vol(K): |
3-Month: 13 (K) 10-Days: 13 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KLDO ] has closed above bottom band by 15.8%. Bollinger Bands are 106% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0 - 0 |
0 - 0 |
|
Low:
|
0 - 0 |
0 - 0 |
|
Close:
|
0 - 0 |
0 - 0 |
|
Company Description |
|
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts. |
Headline News |
Tue, 24 Jan 2023
Johnson & Johnson Reports Q4 and Full-Year 2022 Results - Investing News Network
Wed, 18 Jan 2023
Johnson & Johnson to Participate in the SVB Securities Global Biopharma Conference - Investing News Network
Thu, 15 Dec 2022
Ice Storm Brings Down Two Broadcast Towers In South Dakota. - Inside Radio
Mon, 11 Apr 2022
Kaleido Biosciences Investor Alert: Kaplan Fox Investigates ... - GlobeNewswire
Fri, 08 Apr 2022
KLDO stock crashes on plans to delist from Nasdaq (NASDAQ:KLDO) - Seeking Alpha
Mon, 31 Jan 2022
Kaleido Biosciences cuts staff, COPD program - Boston Business ... - The Business Journals
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: PNK |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
43 (M) |
|
% Held by Insiders
|
4.245e+007 (%) |
|
% Held by Institutions
|
0.7 (%) |
|
Shares Short
|
2,160 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.516e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-7 |
|
Return on Assets (ttm)
|
927.7 |
|
Return on Equity (ttm)
|
-100 |
|
Qtrly Rev. Growth
|
1.1e+006 |
|
Gross Profit (p.s.)
|
186.36 |
|
Sales Per Share
|
-1055.59 |
|
EBITDA (p.s.)
|
-1.21273e+008 |
|
Qtrly Earnings Growth
|
-2.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-77 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.34e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
